PCM
BEAM icon

Prelude Capital Management’s Beam Therapeutics BEAM Stock Holding History

Prelude Capital Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,950
Closed -$241K – 1537
2020
Q4 		$241K Sell
2,950
-2,650
-47% -$130K 0.01% 1021
2020
Q3 		$138K Hold
5,600
– – 0.01% 802
2020
Q2 		$157K Buy
+5,600
New +$121K 0.01% 807

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Prelude Capital Management's BEAM Position: Q1 2021 in Review

Prelude Capital Management sold out of Beam Therapeutics (BEAM) in Q1 2021, closing a stake of 2,950 shares — an estimated $241K sold.

Prelude Capital Management first reported a position in BEAM in Q2 2020 and held it in 3 quarters. The position peaked at $241K in Q4 2020. 209 funds tracked by Wall St. Rank hold BEAM as of Q1 2021.

  • Prelude Capital Management reported no remaining Beam Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Prelude Capital Management sold 2,950 Beam Therapeutics shares in Q1 2021, an estimated $241K.
  • Prelude Capital Management first reported a position in Beam Therapeutics in Q2 2020 and held it in 3 quarters.
  • Prelude Capital Management's Beam Therapeutics position peaked at $241K in Q4 2020.
  • 209 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2021.

Based on Prelude Capital Management's 13F filing for Q1 2021, filed 17 May 2021.